Vaxfectin-formulated tetravalent dengue DNA vaccine: Phase I started

Vical said the Naval Medical Research Center (NMRC) began a Phase I trial in about 40 subjects to compare low- and high-dose Vaxfectin-formulated tetravalent dengue DNA vaccine vs. a tetravalent deng...